Gilead partner Arcus earns analysts’ plaudits for early pancreatic cancer data that ‘exceeded expectations’

Arcus’ small molecule CD73 inhibitor for pancreatic cancer got a standing ovation from analysts who said preliminary data “exceeded expectations”— making waves in a field that’s seen little progress in several years and proving the candidate could be worth the hundreds of millions Gilead provided upfront in a deal that…

Click to view original post